Monthly Archives: November 2009

Aurobindo Pharma aims to treble revenue by 2014

November 20th, 2009|

The drug maker expects sales from the Pfizer alliance to contribute some 25% to its total sales in four years.

A.P. number one in pharma exports

November 20th, 2009|

Chief Minister K. Rosaiah on Friday said Andhra Pradesh led other States in the setting up of pharmaceutical industries and exporting pharma products.

NPPA revises prices of 119 formulation packs

November 20th, 2009|

The National Pharmaceutical Pricing Authority (NPPA) has newly fixed or revised prices of 119 formulation packs and issued corrigendum orders on two insulin formulation packs for which it has revised prices in March, 2009.

Ecron Acunova opens new office in Russia to tap clinical trials opportunities

November 20th, 2009|

Ecron Acunova, a full-service clinical research organization (CRO), with offices across Europe, India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow. Galyna Andriyko will lead the development of the Russian office operations.

Model N to spruce up India Operations

November 19th, 2009|

Model N, a revenue management solutions provider for pharmaceutical, medical devices and biotech companies, on Wednesday said it would invest $8 million in its India operations by financial year 2010-2011.

In healthcare, we can at best play catch-up with China

November 19th, 2009|

Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.

Sun Pharma subsi gets USFDA nod for anti-hypertension drug

November 19th, 2009|

Drug firm Sun Pharmaceutical Industries on Wednesday said that its subsidiary, has received US Drug regulator approval for anti-hypertension drug.

Novo Nordisk eyes India as insulin hub for sub-continent

November 17th, 2009|

Denmark-based world leader in diabetes care Novo Nordisk can look at making India the hub for manufacturing insulin for the sub-continent. The company today inaugurated a dedicated facility with a capacity of 26 million vials per annum in partnership with Ahmedabad based Torrent Pharmaceuticals Ltd. Torrent has been manufacturing insulin for Novo Nordisk since the early nineties.

Suven Life Sciences plans to raise funds for clinical trials

November 17th, 2009|

Suven Life Sciences Ltd, the Hyderabad-based biopharmaceutical company that is working on 10 new molecules for central nervous system (CNS) disorders or ailments, plans to raise funds for further trials on one of these, SUVN-502.

OncQuest Laboratories announces UGT1 A1 GENOTYPING

November 17th, 2009|

An effective tool for predicting therapeutic response of Irinotecan in colorectal cancers After building trust with its innovative diagnostic tools, OncQuest Laboratories Ltd. – the pioneer in the Indian Oncology clinical testing, today announced the launch of UGT1A1 Genotyping for determining therapeutic response of Irinotecan, a chemotherapy drug which has been approved by the Food & Drug Administration, USA (US – FDA) as a second line therapy to treat colorectal cancer that has metastasized (spread to other parts of the body) or has recurred (come back) or gotten worse after earlier chemotherapy. 

BAXTER INDIA INTRODUCES NEW THERAPY IN HEMOPHILIA TREATMENT

November 17th, 2009|

Launches RECOMBINATE a genetically engineered, non-plasma-derived FVIII bringing advanced care to people with Hemophilia in India. Baxter India Private Limited, a wholly owned subsidiary of Baxter International Inc., the global leader in Hemophilia care today announced the launch of RECOMBINATE in India. RECOMBINATE, a genetically engineered non plasma-derived recombinant factor (rFVIII) through increased viral safety and uninterrupted supply, represents a significant step forward in raising the standards of care for people with Hemophilia in India. RECOMBINATE is indicated for the prevention and control of hemorrhagic episodes and for the preoperative management of people with Hemophilia A.   

Dr PV Appaji gets IPGA 2008 Eminent Pharmacy Graduate Award

November 17th, 2009|

Executive director of Pharmaceuticals Export Promotion Council (Pharmexcil) Dr PV Appaji has received the prestigious Indian Pharmacy Graduates Association (IPGA) 'Eminent Pharmacy Graduate Award' for the year 2008 for his outstanding contributions towards the advancement of pharmaceutical profession. Director-general (Drugs Control Administration), Andhra Pradesh, R P Meena presented the award to Dr Appaji.

Medicis deal, generic biz to boost financials

November 16th, 2009|

Recent developments could well be a pointer to better days ahead for Glenmark Pharma which has had a relatively poor performance in the past four quarters.

New NPPA chairman warns drug cos against circumventing pricing norms

November 16th, 2009|

While holding that one of the main tasks ahead for the National Pharmaceutical Pricing Authority (NPPA) to ensure availability of medicines in far flung and inaccessible areas of the country, its newly-appointed chairman Dr S M Jharwal has sent a stern warning to the companies against any attempt to 'circumvent the price fixation and permissible price increase'.

Commerce Ministry & FICCI to organise Namaskar Africa

November 16th, 2009|

The Federation of Indian Chambers of Commerce & Industry (FICCI) along with the Ministry of Commerce and Industry, Government of India and Economic Community of West African States (ECOWAS) is organizing ‘Namaskar Africa’ – an Indian business expedition to Africa from January 14 to 16, 2010 at Lagos, Nigeria. The focus sectors of the initiative include 'healthcare & pharmaceuticals'.

BioInvent inks licensing pact with Daiichi Sankyo to discover & develop therapeutic antibodies

November 16th, 2009|

BioInvent International AB has entered into a licence and discovery agreement with Daiichi Sankyo Company, Limited for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

Cipla’s swine flu drug Antiflu hits market

November 11th, 2009|

At a time when the second wave of swine flu pandemic is likely in the winters, leading pharmaceutical firm Cipla Ltd. introduced a new variant of anti-flu drug Oseltamivir, called Antiflu, to treat H1N1 influenza this Wednesday.

E7 the new El Dorado for pharma

November 11th, 2009|

When one door closes, another opens. What Alexander Graham Bell said ages ago makes perfect sense for the medicinemakers today. With developed markets, for long a lucrative source of revenue, crimped by slowdown, pharma firms are turning attention to the galloping seven in the developing world — Brazil, Russia, India, China (or the famed BRIC), and Mexico, Indonesia, and Turkey –or the E7 — as the new El Dorado.

Watch out for US recovery, new products

November 11th, 2009|

Robust growth in profits despite modest rise in revenues characterised the performance of the Indian pharma sector for the latest quarter ended

Biocon hums with plans, pitches for global top 3 slot

November 9th, 2009|

Biocon was scouting for more strategic alliances and exploring opportunities for outlicensing its biotech drugs under development, as it pitches for a slot among the top three bio-pharmaceutical players across the globe, said Kiran Mazumdar-Shaw, chairman and managing director.